Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNHI 2 is an LDHA inhibitor; reduces lactate production in HeLa cells. Inhibits cell growth of LPC006 and PANC-1 cells in vitro. Enhances the antiproliferative effects of Gemcitabine (Cat. No. 3259) on LPC006 and PANC-1 cells. Also inhibits ferroptosis.
NHI 2 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 335.28 |
Formula | C17H12F3NO3 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 1269802-97-2 |
PubChem ID | 51355147 |
InChI Key | YPPFWRWCZNXINO-UHFFFAOYSA-N |
Smiles | ON2C1=CC(C3=CC=CC=C3)=CC(C(F)(F)F)=C1C=C2C(OC)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 33.53 | 100 | |
ethanol | 33.53 | 100 |
The following data is based on the product molecular weight 335.28. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.98 mL | 14.91 mL | 29.83 mL |
5 mM | 0.6 mL | 2.98 mL | 5.97 mL |
10 mM | 0.3 mL | 1.49 mL | 2.98 mL |
50 mM | 0.06 mL | 0.3 mL | 0.6 mL |
References are publications that support the biological activity of the product.
Maftouh et al (2014) Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcit. against pancreatic cancer cells in hypoxia. Br.J.Cancer 110 172 PMID: 24178759
Calvaresi et al (2013) Dual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. Chembiochem 14 2263 PMID: 24174263
Granchi et al (2013) Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org.Biomol.Chem. 11 6588 PMID: 23986182
Jacobsen et al (2018) APD-containing cyclolipodepsipeptides target mitochondrial function in hypoxic cancer cells. Cell Chem.Biol. 25 1337 PMID: 30122371
If you know of a relevant reference for NHI 2, please let us know.
Keywords: NHI 2, NHI 2 supplier, NHI2, C17H12F3NO3, LDHA, inhibitors, lactate, dehydrogenases, antiproliferative, inhibits, Lactate, Dehydrogenase, A, 5363, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for NHI 2 include:
Jung-Hee et al (2021) Akt-mediated Ephexin1-Ras interaction promotes oncogenic Ras signaling and colorectal and lung cancer cell proliferation. Cell Death Dis 12 1013 PMID: 34711817
Do you know of a great paper that uses NHI 2 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review NHI 2 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.